Latest Conference Articles

Six standout posters were presented on Tuesday that focused on Inflammatory Bowel Disease.

Seven standout studies were presented during this morning's plenary session.

What do gastroenterologists need to know before creating a website for their practice?

The need exists to achieve maximum efficieny in the endo suite while maintaining maximum qualty.

Coding issues remain a moving target in gastroenterology, and one must rely on other sources to remain up to date.

Seven poster presentations focused on ulcerative colitis during the Monday, October 18, poster presentations. Here, each is summarized.

Of the nearly 400 clinical vignettes and case reports presented on Monday, two focused on ulcerative colitis.

ACG unveils enhanced version of GI Circle based on member feedback.

Results from five standout studies were presented during this morning's President's Plenary Session.

The 2010 Cardiometabolic Health Congress will take place October 20-23, 2010, at the Sheraton Hotel, in Boston, MA.

What evidence exists to support the use of antidepressants in patients with irritable bowel syndrome.

The last decade has seen a renewed interest in the bacteria residing within our gastrointestinal tract--the gut microbiota.

Ling Chang, MD, discusses recommendations from the ACG Task Force on management of IBS, and patient-related factors that guide IBS.

Scheduling, event, exhibit hall, CME, and other information for attendees of the 48th Annual Meeting of the Infectious Diseases Society of America.

View schedules, learn about special events and opportunities to earn CME credits, and see what you can do on your down time.

Safety and adverse event monitoring don't stop when a vaccine is approved.

Investigators face several technical, logistical, and cultural challenges when conducting vaccine trials in developing nations.

Although the market is growing, vaccine makers face a variety of technical, research, and business challenges.

Virus-like particles have been used in approved vaccines and several prophylactic and therapeutic vaccine candidates in clinical development.

Ensuring the safety of patients in vaccine clinical trials requires close cooperation between sponsors and vaccine suppliers.

As vaccine manufacturers turn their focus to emerging markets, several technical and logistic hurdles remain to be overcome.

Vaccine that incorporates nanoparticles filled with potent stimulators of the innate immune system proves promising in clinical trials.

Clinicians will need new materials and technologies as medicine becomes more personalized.

A successful government-industry collaboration produced a safer preventive vaccine against this deadly disease.

New vaccine would be the first cell-derived, recombinant protein-based influenza vaccine licensed in the US.

Early positive clinical trial results for a novel nasal influenza vaccine.

Vaccine expert says that there are many lessons to be learned from the response to the most recent H1N1 pandemic.

Researchers studying influenza vaccines were able to achieve immune response with a single vaccination against H1N1.

How a massive operation of medical countermeasures was mobilized to tackle the ever-present threat of influenza in the US and overseas.

Safe and effective new nasal spray-delivered influenza vaccine could be produced quickly in high quantities during a pandemic infection.